Geode Capital Management LLC Buys 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT)

Geode Capital Management LLC lifted its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 4.7% during the third quarter, HoldingsChannel reports. The firm owned 1,668,004 shares of the company’s stock after acquiring an additional 74,194 shares during the quarter. Geode Capital Management LLC’s holdings in Altimmune were worth $10,244,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Barclays PLC increased its stake in shares of Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after purchasing an additional 75,064 shares during the last quarter. Wellington Management Group LLP grew its holdings in Altimmune by 27.5% during the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock worth $1,211,000 after purchasing an additional 42,553 shares during the period. Stifel Financial Corp increased its position in Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after buying an additional 7,746 shares during the last quarter. Centiva Capital LP bought a new stake in Altimmune in the third quarter valued at approximately $120,000. Finally, Bellevue Group AG lifted its position in shares of Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after buying an additional 263,660 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Down 1.5 %

NASDAQ:ALT opened at $7.21 on Thursday. The stock has a 50 day simple moving average of $8.04 and a 200 day simple moving average of $7.16. The stock has a market cap of $512.81 million, a P/E ratio of -4.65 and a beta of 0.15. Altimmune, Inc. has a 1-year low of $5.28 and a 1-year high of $14.84.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter. During the same period in the prior year, the business posted ($0.39) EPS. As a group, sell-side analysts forecast that Altimmune, Inc. will post -1.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ALT. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, November 14th. UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Altimmune presently has an average rating of “Moderate Buy” and an average price target of $20.00.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.